% | $
Quotes you view appear here for quick access.

Infinity Pharmaceuticals, Inc. (INFI) Message Board

earlybreak 6 posts  |  Last Activity: Jul 10, 2015 4:38 PM Member since: May 4, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • earlybreak earlybreak Jul 10, 2015 4:38 PM Flag

    Yes thats why you must put all the morons on ignore.

    Sentiment: Strong Buy

  • Reply to

    Kite getting attention everywhere...

    by contraband73 Jul 1, 2015 11:04 AM
    earlybreak earlybreak Jul 1, 2015 11:26 AM Flag

    JUNO is also in clinical trials with memorial sloan kettering best cancer hospital.IMO

    Sentiment: Strong Buy

  • earlybreak earlybreak Jul 1, 2015 10:31 AM Flag

    One thing, however, is certain: early-stage results of using CAR T therapies in very sick cancer patients have shown tremendous promise, with tumor cells virtually wiped out from the whole body. Since Celgene’s core area of expertise has remained to be gene and protein homeostasis therapies for cancer and inflammatory diseases, a venture into CAR T therapies makes sense for the company. Another thing that makes sense is that the company has essentially beaten off a potential competitor in the arena — Juno — by entering into a partnership with it.Furthermore, the only way Celgene would have gained access to Juno’s technology was through a partnership. A takeover was out of the question. Juno management is unlikely to agree to an acquisition bid priced at even $85 per share (the company closed at $53.33 on Tuesday), considering the soaring valuations and stock prices of its peers.

    Sentiment: Strong Buy

  • Reply to

    JP Morgan analyst weighs in on JUNO

    by hshinti Jul 1, 2015 8:31 AM
    earlybreak earlybreak Jul 1, 2015 8:48 AM Flag

    July 1, 2015 8:24 AM EDT in Analyst News • Healthcare
    On June 29, Juno Therapeutics Inc (NASDAQ:JUNO) and Celgene Corporation (NASDAQ:CELG) announced a ten-year collaboration to develop new therapies for cancer and auto-immune diseases, specifically T cell therapies. Celgene will have the option to commercialize Juno’s programs outside North America, while Juno will be have the ability to co-develop and co-promote certain Celgene therapies.

    CAR T-cell therapy, or chimeric antigen receptors, is a method of treating cancer that harnesses the patient’s own immune system. A patient’s T cells are multiplied and then infused back into the patient in an attempt to fight back against the cancer. Juno currently has several CAR therapies in its pipeline aimed at different forms of leukemia and lymphoma.

    According to the agreement, Celgene will make an initial investment of $1 billion in Juno. This includes buying more than nine million shares of Juno for $93 per share. At the time of the announcement, shares of Juno were trading at $46; nearly half that amount. This signal of confidence caused shares of JUNO to soar over 40% in pre-market trading following the announcement, though the price stabilized during the day and closed at $46.30.

    The partnership will be mutually beneficial, as described by executives of both companies. Celgene CEO Bob Hugin pointed out Juno’s “impressive capabilities and technologies in the areas of T cell biology and cellular therapy.” On the other hand, Juno’s CEO Hans Bishop is looking forward to integrating Celgene’s “leading small molecule and protein capabilities that complement Juno’s advanced engineered T cell capabilities.”

    Although the partnership seems to be a win for both biotechnology companies, Cory Kasimov of J.P. Morgan was more bullish on Juno than Celgene. The analyst reiterated an Overweight rating on Juno and raised his price target from $66 to $83. Kasimov explains, “From JUNO’s perspective, this is clearly a big win; the deal provides a huge infusion of cash as well as validation for the company’s diversified approach within CAR-T, not to mention the overall potential of this nascent field.” Overall, the analyst believes the partnership will make Juno a more competitive player in the biotechnology field thanks to its new advanced capabilities.

    Sentiment: Strong Buy

  • earlybreak by earlybreak Jun 30, 2015 4:14 PM Flag

    JPMorgan analyst Cory Kasimov reiterated an Overweight rating and boosted his price target on Juno Therapeutics (NASDAQ: JUNO) to $83.00 (from $66.00) following the company's 10-year collaboration with Celgene (NASDAQ: CELG).

    "From JUNO’s perspective, this is clearly a big win; the deal provides a huge infusion of cash as well as validation
    for the company’s diversified approach within CAR-T, not to mention the overall potential of this nascent field," Kasimov said. "The capital boost plus CELG’s expertise should add to the potential of the JUNO platform and its capabilities relative to other players."

    He added, "We expect the deal to close in 3Q, and we have updated our model to reflect 1) the $150M upfront payment, which we amortize over the 10yr collab period, 2) the sale of 9.1M shares at $93, and 3) the increase in costs associated with an assumed acceleration of development. On the latter point, JUNO noted it plans to accelerate all the investments it is making, first and foremost in the people it hires, in addition to moving a bit faster across the pipeline and in manufacturing (in addition to continued BD). Given we see this deal as validating JUNO’s approach and somewhat de-risking to a certain extent, we are also lowering our DCF discount rate to 12% (from 13%). The net effect of these changes is an increase in our target to $83 (still a slight discount to the price being paid by CELG)."

    Sentiment: Strong Buy

  • Reply to

    Amtrak Bottomless Pit

    by speedydekker May 14, 2015 11:34 AM
    earlybreak earlybreak May 18, 2015 4:33 PM Flag

    Thats why we have such a big disparity between Big wigs and employees GOP is trying to kill unions .The only why a working person has a chance is with a union.

    Sentiment: Strong Buy

8.74+0.01(+0.11%)Jul 31 4:00 PMEDT